Prostate Cancer
Prostate Cancer is an oncology condition. This overview considers research on whether selected supplements may be relevant to prostate cancer, including Curcumin, Lycopene, Omega-3, and Acetyl-L-Carnitine (ALCAR).
See the oncology context for Prostate Cancer in one focused overview.
This list shows research findings, not treatments. Nothing here replaces medical care. If you have this condition, talk to a doctor.
What may help
None of these options has good evidence yet. Best evidence first.
5 options:4 not enough evidence1 no benefit found
Acceptance and Commitment Therapy (ACT)practiceNot enough evidence
Too few or too small studies to know if it works.
The one study found a benefit.
A feasibility and acceptability study involving 40 people with cancer reported high adherence and improvements in quality of life and fatigue that increased with intervention exposure. There was no control group, so these changes cannot establish that ACT caused the improvements.
Open the Acceptance and Commitment Therapy (ACT) pageBrisk WalkingpracticeNot enough evidence
Too few or too small studies to know if it works.
The one study found a benefit.
A 2025 feasibility study in 110 people with Prostate Cancer found acceptable randomisation and retention, but adherence was below criteria and the study did not provide clinical efficacy data.
Open the Brisk Walking pageFastingpracticeNot enough evidence
Too few or too small studies to know if it works.
The one study found a benefit.
In a randomized trial of 20 people, weight loss from baseline to 6 months was reported in each study arm.
Open the Fasting pagePilatespracticeNot enough evidence
Too few or too small studies to know if it works.
The one study found a benefit.
A 2025 review of randomized and non-randomized human studies reported a reduction in nocturia among patients with prostate cancer.
Open the Pilates pageMeditationpracticeNo benefit found
Studies looked for a benefit and did not find one.
The one study found no benefit.
Open the Meditation page
The expert view shows every study, dose protocol and source.
What may help
Interventions recorded as helping with this condition5 listedThe best we have, but the evidence is still weak
- →PracticesAcceptance and Commitment Therapy (ACT)CertaintyLowSourceClinical
A feasibility and acceptability study involving 40 people with cancer reported high adherence and improvements in quality of life and fatigue that increased with intervention exposure. There was no control group, so these changes cannot establish that ACT caused the improvements.
Who was studied
- People with a condition
- Breast Cancer
- Prostate Cancer
Open Acceptance and Commitment Therapy (ACT)Study result
Feasibility/acceptability study in 40 cancer patients; high adherence and dose-response improvements in QoL/fatigue, but no control group.
- →PracticesBrisk WalkingCertaintyLowSourceClinical
A 2025 feasibility study in 110 people with Prostate Cancer found acceptable randomisation and retention, but adherence was below criteria and the study did not provide clinical efficacy data.
Who was studied
- People with a condition
- Prostate Cancer
Open Brisk WalkingStudy result
Feasibility study showing acceptable randomisation and retention, but adherence below criteria; no clinical efficacy data.
- →PracticesFastingCertaintyLowSourceClinical
In a randomized trial of 20 people, weight loss from baseline to 6 months was reported in each study arm.
Who was studied
- People with a condition
- Overweight
- Prostate Cancer
Open FastingStudy result
Authors report clinically meaningful weight loss in each arm from baseline to 6 months; the intermittent fasting value is truncated in the abstract.
- →PracticesPilatesCertaintyLowSourceClinical
A 2025 review of randomized and non-randomized human studies reported a reduction in nocturia among patients with prostate cancer.
Who was studied
- People with a condition
- Breast Cancer
- Cancer
- Prostate Cancer
Open PilatesStudy result
Reduction of nocturia reported in patients with prostate cancer
Very low probability(1)
- →PracticesMeditationCertaintyVery lowSourceMeta-analysisOpen Meditation
Who was studied
- People with a condition
What to avoid
Interventions recorded as making it worseNothing in this library is currently recorded as making Prostate Cancer worse. Coverage is partial, and absence here is not evidence of safety.
How to read the evidence
Evidence tier — overall strength of the evidence for the whole compound
- StrongWell established — backed by strong, consistent human research.
- ModerateSome genuine support, but mostly from small or lower-quality studies. Promising, not proven.
- PreliminaryEarly-stage evidence — a promising hypothesis, not an established effect yet.
- LimitedVery limited evidence — treat this as a hypothesis, not proof.
- InsufficientNot enough good evidence to draw conclusions yet.
Certainty — how sure we can be that the effect is real
- Very highVery sure — strong, consistent evidence
- HighFairly sure — consistent evidence from good studies
- MediumModerately sure — new studies could change this
- LowNot sure — little or mixed evidence
- Very lowVery unsure — almost no usable evidence
Source — where the data comes from
- Meta-analysisPooled analysis of many trials — the strongest evidence
- RCTRandomized controlled trial — a strong human study design
- ClinicalA human clinical study
- Reference knowledgeFrom general health-science or pharmacology references, not a study of this exact claim
- Animal researchStudied in animals, not humans
- Community reportsAggregated user reports — anecdotal signal, not evidence
- TheoreticalMechanism-based reasoning, not yet tested
Study grade — quality of each underlying study (A best, D weakest)
- AHigh-quality — strong, consistent human trials
- BGood — solid evidence with some limitations
- CModerate — limited, small, or mixed-quality studies
- DWeak — preliminary, indirect, or animal-only
Confidence — how strongly the sources back a finding
A 0–100 score from study quality and agreement
Most supplement evidence is graded C–D. Read it as preliminary signal, not proof.
Full write-up
What is it
Prostate Cancer is an oncology condition. This overview considers research on whether selected supplements may be relevant to prostate cancer, including Curcumin, Lycopene, Omega-3, and Acetyl-L-Carnitine (ALCAR).
The research does not apply uniformly across people: it includes clinical research and animal studies, and some studies do not specify participants’ health status. Findings should therefore be understood as research context rather than a substitute for care for this medical condition.
Evidence-backed options
The options associated with Prostate Cancer span clinical evidence, a meta-analysis of randomized controlled trials, a review, and animal research. This matters because findings from animal models, such as those involving Acetyl-L-Carnitine (ALCAR) and Taurine, do not establish that the same effects occur in people. The animal findings also relate to specific tumor models rather than the full range of prostate cancer cases.
Curcumin has the strongest overall support among the listed options, with clinical evidence indicating inhibitory properties toward prostate tumor growth and a potentially beneficial effect on treatment. Lycopene and Omega-3 also have clinical evidence, but the findings are narrower: lycopene research has focused on anti-cancer activity, while the Omega-3 evidence concerns a possible association between higher intake and lower prostate cancer mortality and notes that more research is needed. The Omega-3 findings include mixed health statuses, which may limit how broadly they apply.
Selenium has been examined in a meta-analysis of randomized controlled trials and is described as potentially protective against prostate cancer development. That focus on development is not the same as evidence for treating established cancer. Vitamin C and Vitamin E have weaker support in this context; the available findings do not establish a clear benefit for Vitamin C, and provide little evidence for Vitamin E in relation to prostate cancer risk.
The evidence described here does not provide dose, duration, or timing information, so it cannot show what was taken, how long it was used, or how quickly an effect might appear. These options should be interpreted alongside cancer diagnosis and treatment details with a clinician.
What to avoid
Horny Goat Weed (Epimedium), Tribulus Terrestris, Tongkat Ali (Eurycoma), and Maca Root are flagged because of possible hormonal effects that may be relevant to prostate cancer. Tribulus Terrestris and Maca Root have been associated with theoretical hormonal stimulation or weak hormonal effects, which is why their use is treated cautiously in hormone-sensitive cancers. Tongkat Ali (Eurycoma) may elevate androgen levels, raising concern about possible effects on prostate cancer progression; this concern applies to active disease and a history of prostate cancer.
Horny Goat Weed (Epimedium) has an additional consideration: possible PDE5 inhibition, alongside potential hormonal effects. In androgen-sensitive prostate cancer, these effects may be contraindicated, and safety has not been established. Because the concerns involve hormone sensitivity, androgen activity, and limited safety information, the relevance may depend on the person’s cancer status and treatment context. Anyone with prostate cancer should discuss these supplements with a clinician before use.